GlassScriptPhysician profile
Nancy D Berube
NPI 1538131867
$14,130.15
in general payments reported to CMS, 2019-2025
44 companies · $2,762 in 2025
The $2,762 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,902 · 2020: $1,855 · 2021: $1,587 · 2022: $1,590 · 2023: $2,026 · 2024: $2,408 · 2025: $2,762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,196.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,959.55 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $1,589.22 | 2019-2025 | |
| Abbvie INC. | $1,481.88 | 2021-2025 | Linzess, Viberzi, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $1,294.22 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,016.26 | 2019-2025 | Jardiance, Synjardy |
| Teva Pharmaceuticals USA, INC. | $893.43 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $626.42 | 2019-2025 | Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $613.94 | 2019-2025 | Xifaxan |
| Allergan, INC. | $588.49 | 2019-2020 | |
| Novo Nordisk INC | $498.85 | 2019-2024 | Rybelsus, Ozempic |
| Astellas Pharma US INC | $374.91 | 2019-2025 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $326.90 | 2022 | |
| Amarin Pharma, INC. | $312.86 | 2019-2022 | |
| Exact Sciences Corporation | $290.04 | 2023-2025 | Cologuard Collection Kit |
| Ardelyx, INC. | $265.52 | 2024-2025 | Ibsrela |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $252.59 | 2023-2025 | |
| Aimmune Therapeutics, INC. | $210.87 | 2025 | Zenpep, Vowst |
| Amgen INC. | $186.27 | 2020-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $164.23 | 2019-2024 | Shingrix, Arexvy |
| Otsuka America Pharmaceutical, INC. | $155.53 | 2023-2025 | Rexulti |
| Inspire Medical Systems, INC. | $153.23 | 2024-2025 | Inspire |
| Phathom Pharmaceuticals, INC. | $100.66 | 2024-2025 | Voquezna |
| Axsome Therapeutics, INC. | $91.40 | 2024-2025 | Auvelity |
| Merck Sharp & Dohme LLC | $69.77 | 2019-2024 | Gardasil 9, Gardasil |
| Biohaven Pharmaceuticals, INC. | $60.98 | 2021 | |
| Novartis Pharmaceuticals Corporation | $57.47 | 2019-2023 | |
| Agios Pharmaceuticals, INC. | $56.08 | 2024-2025 | Pyrukynd |
| Nestle Healthcare Nutrition INC. | $47.72 | 2020-2021 | |
| Daiichi Sankyo INC. | $47.35 | 2022-2023 | Injectafer |
| Boston Scientific Corporation | $38.97 | 2025 | Watchman Access System |
| Esperion Therapeutics, INC. | $31.25 | 2024-2025 | Nexletol |
| Lundbeck LLC | $29.30 | 2025 | Rexulti |
| Acadia Pharmaceuticals INC | $26.46 | 2024 | Nuplazid |
| Genentech USA, INC. | $23.91 | 2022 | |
| Redhill Biopharma INC. | $23.53 | 2020 | |
| Mylan Specialty L.P. | $23.51 | 2024 | Yupelri |
| Madrigal Pharmaceuticals | $23.26 | 2025 | Rezdiffra |
| Abbott Laboratories | $22.97 | 2023 | Freestyle Libre 2 |
| Pulmonx Corporation | $19.72 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Ultragenyx Pharmaceutical INC. | $19.70 | 2023 | |
| Kyowa Kirin, INC. | $18.03 | 2023 | Crysvita |
| Echosens North America, INC. | $16.04 | 2025 | Fibroscan |
| Idorsia Pharmaceuticals US INC | $15.17 | 2023 | Quviviq |
| Scilex Pharmaceuticals INC. | $11.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Berube listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.